Costs and healthcare use of patients with chronic kidney disease in the Northern Territory, Australia

Author:

Chen Winnie,Howard Kirsten,Gorham Gillian,Abeyaratne Asanga,Zhao Yuejen,Adegboye Oyelola,Kangaharan Nadarajah,Talukder Mohammad Radwanur Rahman,Taylor Sean,Cass Alan,

Abstract

Abstract Background The burden of chronic kidney disease (CKD) is high in the Northern Territory (NT), Australia. This study aims to describe the healthcare use and associated costs of people at risk of CKD (e.g. acute kidney injury, diabetes, hypertension, and cardiovascular disease) or living with CKD in the NT, from a healthcare funder perspective. Methods We included a retrospective cohort of patients at risk of, or living with CKD, on 1 January 2017. Patients on kidney replacement therapy were excluded from the study. Data from the Territory Kidney Care database, encompassing patients from public hospitals and primary health care services across the NT was used to conduct costing. Annual healthcare costs, including hospital, primary health care, medication, and investigation costs were described over a one-year follow-up period. Factors associated with high total annual healthcare costs were identified with a cost prediction model. Results Among 37,398 patients included in this study, 23,419 had a risk factor for CKD while 13,979 had CKD (stages 1 to 5, not on kidney replacement therapy). The overall mean (± SD) age was 45 years (± 17), and a large proportion of the study cohort were First Nations people (68%). Common comorbidities in the overall cohort included diabetes (36%), hypertension (32%), and coronary artery disease (11%). Annual healthcare cost was lowest in those at risk of CKD (AUD$7,958 per person) and highest in those with CKD stage 5 (AUD$67,117 per person). Inpatient care contributed to the majority (76%) of all healthcare costs. Predictors of increased total annual healthcare cost included more advanced stages of CKD, and the presence of comorbidities. In CKD stage 5, the additional cost per person per year was + $53,634 (95%CI 32,769 to 89,482, p < 0.001) compared to people in the at risk group without CKD. Conclusion The total healthcare costs in advanced stages of CKD is high, even when patients are not on dialysis. There remains a need for effective primary prevention and early intervention strategies targeting CKD and related chronic conditions.

Publisher

Springer Science and Business Media LLC

Reference46 articles.

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150.

2. Anderson K, Cunningham J, Devitt J, Preece C, Cass A. “Looking back to my family”: Indigenous Australian patients’ experience of hemodialysis. BMC Nephrol. 2012;13(1): 114.

3. Hughes JT, Freeman N, Beaton B, Puruntatemeri AM, Hausin M, Tipiloura G, et al. My experiences with kidney care: A qualitative study of adults in the Northern territory of Australia living with chronic kidney disease, dialysis and transplantation. PLoS One. 2019;14(12):e0225722.

4. Kerr M, Evangelidis N, Abbott P, Craig JC, Dickson M, Scholes-Robertson N, et al. Indigenous peoples’ perspectives of living with chronic kidney disease: systematic review of qualitative studies. Kidney Int. 2022;102(4):720–7.

5. Kidney Health Australia. State of the Nation: Chronic Kidney Disease in Australia: Kidney Health Australia; 2016. Available from: https://kidney.org.au/uploads/resources/state-of-the-nation-kidney-health-week-2016-chronic-kidney-disease-hot-spots.pdf. Cited Sept. 2023.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3